Preclinical toxicity screening array for novel antiviral compounds

The trainees of this project will develop methods and techniques to test the effects of antivirals on white blood cells and set up a platform to test the preclinical toxicity of new potential antiviral compounds. White blood cells can exacerbate viral infections, yet there are few studies on how antivirals may have off target effects on these cells. Such studies can lead to more in-depth studies on white blood cells as to how they may affect infection outcomes. The preclinical toxicity testing platform can facilitate the lead optimization stage of new potential antiviral (and other) drugs, so they can be developed more efficiently into therapeutics.

Faculty Supervisor:

Arno Siraki

Student:

Partner:

Applied Pharmaceutical Innovation

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services; Retail trade

University:

University of Alberta

Program: